AMINO ACID FORMULA AS A FIRST-LINE DIAGNOSIS TOOL IN INFANTS WITH COW'S MILK ALLERGY (CMA): A COST-EFFECTIVENESS ANALYSIS UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE

被引：1

作者：

Castro, A. P. B. M. ^{[1
]}

Morais, M. B. D. ^{[1
]}

Cardoso, A. L. ^{[1
]}

Vieira, M. C.

Spolidoro, J. V. N. ^{[2
,3
]}

Nishikawa, A. M. ^{[4
]}

Clark, O. A. C. ^{[4
]}

机构：

[1] Univ Sao Paulo, BR-05508 Sao Paulo, Brazil

[2] Hosp Pequeno Principe, Curitiba, Parana, Brazil

[3] Pontificia Univ Catolica Rio Grande do Sul, Porto Alegre, RS, Brazil

[4] Evidencias, Campinas, SP, Brazil

来源：

VALUE IN HEALTH | 2014年 / 17卷 / 03期

关键词：

D O I：

10.1016/j.jval.2014.03.1025

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PRS39

引用

页码：A176 / A176

页数：1

共 21 条

[1] Cost-effectiveness of using an extensively hydrolysed formula compared to an amino acid formula as first-line treatment for cow milk allergy in the UK
Taylor, Riza R.
Sladkevicius, Erikas
Panca, Monica
Lack, Gideon
Guest, Julian F.
[J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2012, 23 (03) : 240 - 249
[2] Response to: Cost-effectiveness of using an extensively hydrolysed formula compared to an amino acid formula as first-line treatment for cow milk allergy in the UK
Petrus, N. C. M.
Hulshof, L.
Rutjes, N. W. P.
de Vreede, I.
van Aalderen, W. M. C.
Sprikkelman, A. B.
[J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2012, 23 (07) : 686 - 686
[3] Response to: Cost-effectiveness of using an extensively hydrolysed formula compared to an amino acid formula as first-line treatment for cow milk allergy in the UK Reply
Taylor, Riza R.
Sladkevicius, Erikas
Panca, Monica
Lack, Gideon
Guest, Julian F.
[J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2012, 23 (07) : 687 - 687
[4] Cost-effectiveness of using an extensively hydrolyzed casein formula plus the probiotic Lactobacillus rhamnosus GG compared to an extensively hydrolyzed formula alone or an amino acid formula as first-line dietary management for cow's milk allergy in the US
Ovcinnikova, Olga
Panca, Monica
Guest, Julian F.
[J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 145 - 152
[5] COST-EFFECTIVENESS OF NIVOLUMAB VERSUS DACARBAZINE IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA FROM BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Casagrande Oliveira, A. P.
Hamza, S.
Koloszuk, A.
Marinheiro, P.
Bernardino, G.
[J]. VALUE IN HEALTH, 2020, 23 : S41 - S41
[6] Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective (vol 43, pg S1, 2021)
Salvino, M. A.
Bonfim, C.
Calado, R. T.
Kim, H.
Bertinato, J. F.
Scheinberg, P.
[J]. HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2022, 44 (02) : 1 - 1
[7] COST-EFFECTIVENESS ANALYSIS OF THROMBOLYSIS WITH RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (ALTEPLASE) FOR ACUTE ISCHEMIC STROKE UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Teich, V
Passos, R. B. F.
Vianna, D.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A503 - A503
[8] COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN ETEXILATE VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Fernandes, R. A.
Quintella, F. F.
Teich, V. D.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A502 - A502
[9] COST-EFFECTIVENESS EVALUATION OF AMPHOTERICIN B, AMPHOTERICIN B LIPOSOMAL, CASPOFUNGIN AND VORICONAZOL IN TREATING ASPERGILLOSIS UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Fujii, R. K.
Manfrin, D. F.
Lanzara, G. D. A.
Hajek, P.
Mould, J.
[J]. VALUE IN HEALTH, 2013, 16 (03) : A89 - A89
[10] COST-EFFECTIVENESS ANALYSIS OF SORAFENIB ASSOCIATED TO BEST SUPPORTIVE CARE (BSC) VERSUS BEST SUPPORTIVE CARE ALONE IN THE SECOND LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Teich, V
Fernandes, R. A.
Schiola, A.
[J]. VALUE IN HEALTH, 2009, 12 (03) : A42 - A42

← 1 2 3 →